Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clone6HM CAR-T
- Development stage
- Preclinical
- Modality
- Gene Addition/Replacement → Gene Therapies, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Clone6HM CAR-T is an experimental chimeric antigen receptor (CAR) T-cell therapy designed to target the CD33 antigen, a 67-kDa transmembrane glycoprotein predominantly expressed on the surface of acute myeloid leukemia (AML) blasts and leukemic stem cells. The therapy utilizes T cells genetically modified to express a CAR incorporating a humanized single-chain variable fragment (scFv) derived from the Clone 6 antibody (Clone6HM). This humanized binder is intended to reduce the potential for host immune rejection compared to murine-based CARs, thereby enhancing the persistence and therapeutic window of the cells. Upon administration, Clone6HM CAR-T cells recognize and bind to CD33-positive cells, triggering T-cell activation, cytokine release, and direct cytotoxic killing of the leukemic cells. It is currently being investigated as a targeted immunotherapy for patients with relapsed or refractory AML.
- Other names
- Humanized anti-CD33 CAR-T (Clone6HM)anti-CD33 Clone6HM CAR-Tanti-CD-33 Clone6HM CAR-Tanti-CD 33 Clone6HM CAR-TCD33-targeted CAR-T (Clone6HM)
02
Targets
CD33 (Myeloid cell surface antigen CD33)
Beyond the preview
Go deeper on Clone6HM CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Clone6HM CAR-T.